The Food and Drug Administration yesterday warned that Curative’s SARS-Cov-2 test could produce false results and that health care providers should strictly follow its authorization and labeling.

FDA reiterated that the real-time RT-PCR test must be limited to symptomatic individuals within 14 days of symptom onset; trained health care workers must directly observe the specimen collection; and that a negative result does not rule out COVID-19 infection. In addition, FDA said providers should consider retesting patients using a different test if they suspect an inaccurate result, with any problems with the test reported to the agency directly.

Related News Articles

Headline
The Department of Health and Human Services has renewed the COVID-19 public health emergency declaration for another 90 days effective Oct. 18. The extension…
Headline
The National Institutes of Health yesterday awarded a total of $78 million in funding to develop and manufacture 12 new rapid diagnostic tests for SARS-CoV-2,…
Headline
Abbott Molecular Inc. yesterday issued a recall for its Alinity m SARS-CoV-2 AMP Kits and Alinity m Resp-4-Plex AMP Kits, distributed between May 13, 2020, and…
Headline
The Centers for Disease Control and Prevention yesterday released an operational planning guide for pediatric COVID-19 vaccination and preliminary information…
Headline
Available data support the safety and effectiveness of the Johnson & Johnson COVID-19 vaccine for emergency use authorization as a booster dose in…
Headline
A Food and Drug Administration advisory panel today voted unanimously to recommend an extra Moderna booster dose for certain individuals. The Vaccines and…